Atricure (ATRC) Q2 2024: International Revenue Jumps 29%, Offsetting U.S. Hybrid Headwinds
International momentum and innovation launches propelled Atricure through a quarter of mixed geographic and segment dynamics. While U.S. hybrid and MIS volumes softened due to PFA adoption, robust international gains and open procedure growth kept the company on track for double-digit expansion. Management sharpened its outlook, emphasizing new product launches and clinical trial progress as catalysts for the second half and beyond.
Summary
- Global Expansion Delivers: International sales acceleration offset U.S. hybrid therapy softness.
- Innovation Pipeline Moves: New product launches and clinical trial enrollment drive future growth levers.
- Guidance Reset: Management narrows 2024 outlook, balancing short-term disruption with long-term confidence.
Business Overview
Atricure develops, manufactures, and sells surgical devices for the treatment of atrial fibrillation (AFib) and post-operative pain. The company’s core revenue streams are its ablation franchise (devices for surgical AFib treatment), appendage management (devices for closing the heart’s left atrial appendage), and pain management (cryo-neuroblock therapy). Sales are split between the U.S. (open and minimally invasive procedures) and international markets, with a growing focus on global expansion and new product innovation.
Performance Analysis
Atricure delivered 15% year-over-year revenue growth in Q2, with international markets the standout—rising over 29% and now representing nearly 18% of total revenue. In the U.S., open ablation and open appendage management drove solid double-digit growth, while minimally invasive (MIS) ablation and appendage sales lagged due to physician focus shifting to pulsed field ablation (PFA) catheter launches. Pain management, led by Cryosphere Plus, saw accelerated adoption and strong account expansion.
Gross margin contracted by 170 basis points due to less favorable product and geographic mix. Operating expenses grew in line with revenue, reflecting targeted R&D and commercial investment, especially in clinical trials and product launches. Adjusted EBITDA remained positive, and the company generated over $8 million in quarterly cash flow, reinforcing its commitment to sustained profitability and self-funding growth.
- International Outperformance: Europe and Asia Pacific posted 33% and 23% growth, respectively, fueled by underpenetrated markets and new product momentum.
- Open Procedure Strength: U.S. open ablation and appendage management outpaced overall growth, with Encompass clamp and Atroclip FlexV driving adoption.
- Hybrid/MIS Drag: U.S. hybrid therapy and MIS appendage management volumes declined as physicians prioritized PFA adoption and workflow changes.
While the top line remains robust, the segment mix and temporary U.S. hybrid headwinds warrant close monitoring as new technologies reshape referral and treatment patterns.
Executive Commentary
"We achieved total revenue of $116 million, reflecting over 15% growth, driven by increasing demand across our portfolio of technologies. Our results were underscored by accelerated growth in several areas of business, including U.S. pain management, U.S. open appendage management, and across our international franchises."
Mike Carroll, President and Chief Executive Officer
"We delivered exceptional performance across our international franchises, driving total international revenue of $20.7 million, up 29.4%... We expect momentum throughout our international business to continue for the remainder of 2024."
Angie Weirich, Chief Financial Officer
Strategic Positioning
1. International Acceleration
International markets are now Atricure’s fastest-growing segment, with Europe and Asia Pacific both benefiting from focused commercial execution, underpenetration, and tailored product launches. The company expects continued momentum as it brings its latest innovations, like the Encompass clamp and Atroclip Flex Mini, to these regions, and leverages distributor partnerships in China following recent regulatory clearance.
2. Innovation and Product Launches
Rapid product innovation remains a core growth lever. The launch of Cryosphere Plus and upcoming Cryosphere Max in pain management, as well as the FDA-cleared Atroclip Flex Mini for appendage management, are designed to reduce procedure time and expand addressable markets. Management is also investing in clinical evidence, with the LEAPS stroke reduction trial expected to support expanded indications and future adoption.
3. Navigating PFA Disruption
PFA catheter adoption is causing near-term disruption in U.S. hybrid and MIS volumes, as physicians focus on new workflows and technology integration. However, management views this as temporary, citing European experience where hybrid procedures rebounded as PFA failures accumulated, expanding the patient funnel for Atricure’s therapies. The company is positioning its hybrid and open solutions as complementary to PFA, not competitive.
4. Market Leadership and Competitive Dynamics
Competition in open appendage management is intensifying, but Atricure’s Atroclip platform remains sticky with customers, and new entrants are seen as market validators rather than threats. The company’s high penetration in U.S. cardiac surgery centers means growth is driven by deeper usage within accounts and product innovation rather than new account wins.
5. Clinical and Regulatory Progress
Clinical trial execution is a strategic pillar, with over 2,900 patients enrolled in the LEAPS study and a path to complete enrollment by mid-2025. Regulatory wins, including FDA and China clearances, are setting up future growth levers and global expansion, though near-term revenue impact from China is expected to be modest.
Key Considerations
This quarter’s results highlight Atricure’s ability to balance geographic and segment volatility with innovation and disciplined execution. The company is navigating disruptive technology cycles, while investing in new product launches and clinical evidence to reinforce future growth.
Key Considerations:
- International Growth Engine: Sustained double-digit expansion abroad is now a critical offset to U.S. hybrid headwinds.
- Product Launch Cadence: Cryosphere Max and Atroclip Flex Mini launches are expected to drive second-half adoption and refresh core franchises.
- PFA Distraction vs. Long-Term Funnel: Management sees PFA as a short-term drag but a long-term funnel builder for hybrid therapies.
- Cost and Margin Management: Gross margin compression reflects mix, but operating leverage and cash flow discipline are holding steady.
- Clinical Data as Differentiator: Ongoing trials and new evidence will be vital for market access and competitive positioning in 2025 and beyond.
Risks
Short-term risks center on U.S. hybrid/MIS volume softness as PFA adoption distracts physicians and shifts referral patterns. Margin pressure from product and geographic mix could persist if international and lower-margin products outpace U.S. open growth. Competitive intensity in appendage management and execution risk on product launches remain areas to watch, as does the pace of clinical trial enrollment and regulatory approvals. Management’s guidance assumes hybrid volumes recover post-PFA adoption, but this recovery is not guaranteed in the near term.
Forward Outlook
For Q3 2024, Atricure guided to:
- Low single-digit sequential revenue decline due to typical summer seasonality
- Modest adjusted EBITDA improvement over Q3 2023
For full-year 2024, management maintained guidance of:
- Revenue of $456 to $461 million (about 15% growth over 2023)
- Adjusted EBITDA of $26 to $29 million
- Adjusted loss per share of $0.74 to $0.82
Management cited these factors shaping the outlook:
- Continued international and open procedure momentum
- Product launches and clinical trial progress as second-half catalysts
- Temporary hybrid/MIS headwinds from PFA distraction
Takeaways
Atricure’s Q2 showcased the company’s ability to offset U.S. hybrid procedure softness with international expansion and innovation-driven growth. Despite near-term disruption from PFA adoption, the company remains focused on market expansion, product launches, and leveraging clinical evidence to drive future adoption.
- International and Open Franchise Resilience: Non-U.S. and open procedure strength provided ballast as U.S. hybrid/MIS volumes dipped.
- Innovation Pipeline Is Key: Cryosphere Max and Atroclip Flex Mini launches are set to refresh core franchises and support H2 growth.
- Watch PFA Impact and Hybrid Recovery: The pace of hybrid therapy recovery post-PFA adoption will be a critical variable for 2025 and beyond.
Conclusion
While U.S. hybrid therapy faces short-term headwinds, Atricure’s diversified portfolio, disciplined execution, and robust innovation agenda position it for continued double-digit growth and expanding global relevance. Investors should watch the interplay between PFA adoption, hybrid therapy recovery, and international momentum as key drivers of future performance.
Industry Read-Through
Atricure’s quarter highlights the disruptive impact of new ablation technologies like PFA on established procedural workflows and referral patterns in cardiac surgery. The temporary volume shifts seen in hybrid and minimally invasive procedures may echo across other device makers exposed to similar technology cycles. International growth, underpenetrated markets, and rapid product innovation are proving essential for medtech companies to offset domestic volatility. The importance of clinical evidence and regulatory agility is underscored by Atricure’s investment in trials and global launches—signals that will resonate for peers navigating evolving treatment paradigms in structural heart and electrophysiology markets.